Search Results - "Tuzi, A."

Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience by Luciani, A., Toschi, L., Fava, S., Cortinovis, D., Filipazzi, V., Tuzi, A., Marra, A., Rossi, S., Rossi, A., Blasi, M., Violati, M., Sala, L., Agustoni, F., Bidoli, P., Zonato, S., Ferrari, D.

Get full text

Simultaneous Home Care project for frail advanced cancer patients: a model of integration between no profit and Public Health System by Chini, C., Bascialla, L., Gobba, S., Tuzi, A., Tinelli, G., Pomarico, R., Giani, N., Flore, M., Reato, S., Pinotti, G.

Get full text

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes by Cortellini, A., Leonetti, A., Catino, A., Pizzutillo, P., Ricciuti, B., De Giglio, A., Chiari, R., Bordi, P., Santini, D., Giusti, R., De Tursi, M., Brocco, D., Zoratto, F., Rastelli, F., Citarella, F., Russano, M., Filetti, M., Marchetti, P., Berardi, R., Torniai, M., Cortinovis, D., Sala, E., Maggioni, C., Follador, A., Macerelli, M., Nigro, O., Tuzi, A., Iacono, D., Migliorino, M. R., Banna, G., Porzio, G., Cannita, K., Ferrara, M. G., Bria, E., Galetta, D., Ficorella, C., Tiseo, M.

“…Background In most cases, T790M EGFR -positive NSCLC patients receiving osimertinib developed “non-drugable” progression, as the patients with common EGFR…”
Get full text

Analysis of circulating biomarkers in a randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study by Boeri, M., Nichetti, F., Porcu, L., Torri, V., Del Conte, A., Martinetti, A., Sottotetti, E., Vattemi, E., Verderame, F., Garassino, M.C., Cavanna, L., Tuzi, A., Irtelli, L., de Braud, F.G.M., Platania, M.

Get full text

Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program by Metro, G., Passaro, A., Lo Russo, G., Bonanno, L., Giusti, R., Gregorc, V., Capelletto, E., Martelli, O., Cecere, F.L., Giannarelli, D., Luciani, A., Bearz, A., Tuzi, A., Scotti, V., Tonini, G., Galetta, D., Carta, A., Soto Parra, H., Morabito, A., Chiari, R.

Get full text

Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406] by Cantini, L., Mentrasti, G., Lo Russo, G., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., La Verde, N., Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E.G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D’Emilio, V., Cona, M.S., Guida, A., Caglio, A., Salerno, F., Spinelli, G.P., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, M.V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M.B.L., Berardi, R.

Get full text

Synthesis, Structure, and Second-Order Nonlinear Optical Properties of Copper(II) and Palladium(II) Acentric Complexes with N-Salicylidene-N ‘-aroylhydrazine Tridentate Ligands by Cariati, F, Caruso, U, Centore, R, Marcolli, W, Maria, A. De, Panunzi, B, Roviello, A, Tuzi, A

“…Two new N-salicylidene-N ‘-aroylhydrazines ligands have been prepared:  N-4-diethylaminosalicylidene-N ‘-4-nitrobenzoyl-hydrazine (L1) and…”
Get full text

141P TRICHOMEGALY OF THE EYELASH INDUCED BY ERLOTINIB THERAPY by Iacovelli, R, Palazzo, A, Trenta, P, Cimadon, B, Tuzi, A, Pellegrino, A, Cortesi, E, Naso, G

Get full text

New NLO active cyclopalladated chromophores in main-chain polymers by Cariati, F., Caruso, U., Centore, R., De Maria, A., Fusco, M., Panunzi, B., Roviello, A., Tuzi, A.

“…Four new OH-functionalised orthopalladated complexes bearing an electron-donor and an acceptor group (X or Y) in a trans-like arrangement respect to the metal…”
Get full text

Optical second order nonlinearities in new chromophores obtained by selective mono-reduction of dinitro precursors by Cariati, F., Caruso, U., Centore, R., De Maria, A., Fusco, M., Panunzi, B., Roviello, A., Tuzi, A.

“…Three new push–pull chromophores of potential interest in second order nonlinear optical applications were synthesized and characterized, also by EFISH…”
Get full text

417P - Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumours: A single institution analysis by Nerone, M., Caspani, F., Tralongo, A.C., Tuzi, A., Pinotti, G.

“…Standard of care of high grade glia tumors is represented by concomitant temozolomide (TMZ) and radiotherapy (RT), followed by maintenance TMZ. In clinical…”
Get full text

Effect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumours: A single institution analysis by Nerone, M., Caspani, F., Tralongo, A.C., Tuzi, A., Pinotti, G.

Get full text

6081 Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial by Masi, G, Salvatore, L, Fornaro, L, Vasile, E, Baldi, G.G, Stasi, I, Ciarlo, A, Tuzi, A, Andreuccetti, M, Falcone, A

Get full text

417PEffect of cumulative dose of maintenance temozolomide on overall survival in patients with high grade glia tumours: A single institution analysis by Nerone, M, Caspani, F, Tralongo, A C, Tuzi, A, Pinotti, G

“…Abstract Background Standard of care of high grade glia tumors is represented by concomitant temozolomide (TMZ) and radiotherapy (RT), followed by maintenance…”
Get full text

Survey on prevalence and management of breakthrough cancer pain: a single center experience by Bolzacchini, E., Tuzi, A., Vallini, I., Pinotti, G.

Get full text

868P A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts) by Bossi, P., Resteghini, C., Orlandi, E., Nicolai, P., Vischioni, B., Castelnuovo, P., Turri-Zanoni, M., Ferrari, M., Rampelli, V., Facchinetti, N., Gambazza, S., Calareso, G., Quattrone, P., Ingargiola, R., Cavallo, A., Franceschini, M., Tuzi, A., Mariani, L., Licitra, L.F.

Get full text

Crystal structure of 2,2,3,3,4,4,5,5-octafluorohexanedioic acid dihydrate, (HOOC)C4F8(COOH) · 2H2O by Centore R., Tuzi A.

Get full text

863P - Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC) by Tralongo, P., Bordonaro, S., Lorenzo, G Di, Borsellino, N., Facchini, G., Rossetti, S., Martelli, V., Longo, V., Tralongo, A.C., Caspani, F., Tuzi, A., Spada, M., Calvani, N., Carlini, P., De Giorgi, U.F.F.

“…Cabazitaxel (CAB) was marketed in 2012 in Italy, based on overall survival (OS) benefit demonstrated on the TROPIC study in mCRPC post-docetaxel. The efficacy…”
Get full text

Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC) by Tralongo, P., Bordonaro, S., Lorenzo, G Di, Borsellino, N., Facchini, G., Rossetti, S., Martelli, V., Longo, V., Tralongo, A.C., Caspani, F., Tuzi, A., Spada, M., Calvani, N., Carlini, P., De Giorgi, U.F.F.

Get full text

863PCabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC) by Tralongo, P, Bordonaro, S, Lorenzo, G Di, Borsellino, N, Facchini, G, Rossetti, S, Martelli, V, Longo, V, Tralongo, A C, Caspani, F, Tuzi, A, Spada, M, Calvani, N, Carlini, P, Giorgi, U F F De

“…Abstract Background Cabazitaxel (CAB) was marketed in 2012 in Italy, based on overall survival (OS) benefit demonstrated on the TROPIC study in mCRPC…”
Get full text